By Helena Smolak
AstraZeneca is scheduled to report results for the fourth quarter on Thursday. Here is what you need to know.
SALES FORECAST: The British pharmaceutical giant's total sales are expected to be $14.2 billion for the three months ended Dec. 31, up from $12.02 billion in the same quarter a year prior, according to a company-compiled consensus based on 19 analysts' estimates.
CORE EARNINGS PER SHARE: Core earnings per share are expected to rise to $2.07 from $1.45 the year prior, according to the same consensus.
AstraZeneca's stock is up 7.9% since the start of 2024.
WHAT TO WATCH
--PIPELINE & OUTLOOK: Market watchers will closely monitor AstraZeneca's confidence in the potential of its experimental drug for advanced lung cancer datopotamab deruxtecan, Jefferies analysts said. Industry watchers also eye AstraZeneca's development strategy and differentiation of its obesity portfolio, Jefferies said. The company's 2025 outlook will be crucial as this year sees more than 10 key late-stage trials, UBS analysts said.
--CHINA: Investors' focus will lie on the impact of the continuing anti-corruption investigation into some of AstraZeneca's employees in China on its sales in the country, according to Jefferies. The company is under regulatory scrutiny in China as part of an anticorruption crackdown by authorities after its top executive in the region was detained and while other employees are subject to an investigation about illegal importation of cancer drugs and patient data collection.
Write to Helena Smolak at helena.smolak@wsj.com
(END) Dow Jones Newswires
February 04, 2025 11:19 ET (16:19 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。